Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23990535 | 0.89 | NPC1 (0.33) | NPC1PKMMBOAT4POLBKDR | |
| SCHEMBL24769599 | 0.87 | — | — | |
| SCHEMBL23991232 | 0.85 | PKM (0.36) | NPC1PKMMBOAT4POLBKDM4E | |
| SCHEMBL25745169 | 0.83 | ATM (0.33) | — | |
| SCHEMBL30281146 | 0.81 | PIK3CA (0.33) | ALDH1A1 | |
| SCHEMBL23989770 | 0.81 | PKM (0.34) | NPC1PKMMBOAT4POLBKDM4E | |
| Lithium Ion SCHEMBL30281281 | 0.80 | — | — | |
| SCHEMBL4784779 | 0.79 | ABL1 (0.35) | NPC1KDM4EALDH1A1HPGD | |
| SCHEMBL23990544 | 0.78 | PKM (0.33) | NPC1PKMMBOAT4KDM4EALDH1A1 | |
| SCHEMBL23991047 | 0.78 | TP53 (0.36) | NPC1PKMPOLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| CN-115884810-A | Imidazopyridazines as IL-17 modulators | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20230081548-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NPC1 2744/4885PKM 3476/4885MBOAT4 4794/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NPC1 2744/4885PKM 3476/4885MBOAT4 4794/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NPC1 2744/4885PKM 3476/4885MBOAT4 4794/4885 |
| US-20230081548-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NPC1 2744/4885PKM 3476/4885MBOAT4 4794/4885 |
| US-20220402922-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NPC1 2744/4885PKM 3476/4885MBOAT4 4794/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NPC1 2744/4885PKM 3476/4885MBOAT4 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.